Alemtuzumab Treatment of Intermediate-1 Myelodysplasia Patients Is Associated With Sustained Improvement in Blood Counts and Cytogenetic Remissions

PURPOSE: Myelodysplastic syndromes (MDS) are characterized by ineffective hematopoiesis and progression to leukemia. Clinical and experimental evidence suggests an immune-mediated pathophysiology in some patients, in whom immunosuppressive therapy (IST) with horse antithymocyte globulin (h-ATG) and...

詳細記述

保存先:
書誌詳細
主要な著者: Sloand, Elaine M., Olnes, Matthew J., Shenoy, Aarthie, Weinstein, Barbara, Boss, Carol, Loeliger, Kelsey, Wu, Colin O., More, Kenneth, Barrett, A. John, Scheinberg, Phillip, Young, Neal S.
フォーマット: Artigo
言語:Inglês
出版事項: American Society of Clinical Oncology 2010
主題:
Original Reports
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC3020689/
https://ncbi.nlm.nih.gov/pubmed/21041705
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2010.29.7010
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料